Keith Alcorn

3 weeks ago | aidsmap.com | Keith Alcorn

Estimated reading time 4 minutes There have been almost no scientific studies of the effectiveness of HIV pre-exposure prophylaxis (PrEP) in central or eastern Europe. However, a recent study of 887 PrEP users, all gay and bisexual men, in the Polish city of Wroclaw, found only nine HIV infections (1% of PrEP users) over a three-year period from 2020 to 2023. All 887 PrEP users took oral tenofovir disoproxil/emtricitabine (TDF/FTC) pills.

1 month ago | aidsmap.com | Keith Alcorn

Estimated reading time 10 minutes While plans for global access to lenacapavir, the twice-yearly injectable PrEP product which demonstrated extraordinary efficacy last year, have progressed unusually quickly, critics say that the arrangements are riddled with inconsistencies and will not achieve Gilead Science’s stated goals of “ensuring broad, sustainable global access to lenacapavir for PrEP” and of “ending new HIV infections around the world”.

1 month ago | aidsmap.com | Keith Alcorn

Estimated reading time 7 minutes Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective antiretroviral treatment, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco.

1 month ago | aidsmap.com | Keith Alcorn

Estimated reading time 10 minutes Two slides presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco starkly illustrated the cost of the almost-complete defunding of HIV pre-exposure prophylaxis (PrEP) provision via PEPFAR, the US President’s Emergency Plan for AIDS Relief.

1 month ago | aidsmap.com | Keith Alcorn

Estimated reading time 3 minutes Statin treatment may reduce cardiovascular risk in people with HIV not only by lowering cholesterol but also by reducing coronary plaque and inflammation, Professor Steven Grinspoon told the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week.